Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial.

@article{Smallridge2013EfatutazoneAO,
  title={Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial.},
  author={Robert C. Smallridge and John A. Copland and Marcia S. Brose and Jeffrey Wadsworth and Yariv Houvras and Michael E Menefee and Keith C Bible and Manisha Hasmukhray Shah and Ann W Gramza and Joshua P. Klopper and Laura A. Marlow and Michael G Heckman and Reinhard von Roemeling},
  journal={The Journal of clinical endocrinology and metabolism},
  year={2013},
  volume={98 6},
  pages={2392-400}
}
PURPOSE A phase 1 study was initiated to determine the safety, potential effectiveness, and maximal tolerated dose and recommended phase 2 dose of efatutazone and paclitaxel in anaplastic thyroid cancer. EXPERIMENTAL DESIGN Patients received efatutazone (0.15, 0.3, or 0.5 mg) orally twice daily and then paclitaxel every 3 weeks. Patient tolerance and outcomes were assessed, as were serum efatutazone pharmacokinetics. RESULTS Ten of 15 patients were women. Median age was 59 years. Seven… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 23 extracted citations

Rare Thyroid Malignancies: an Overview for the Oncologist.

Clinical oncology (Royal College of Radiologists (Great Britain)) • 2017
View 1 Excerpt

Spanish consensus for the management of patients with anaplastic cell thyroid carcinoma.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico • 2017

Similar Papers

Loading similar papers…